Skip to main content

Table 1 Phase 1 studies of newer radiosensitizers including platinum compounds

From: Radiosensitizers in cervical cancer. Cisplatin and beyond

Agent [ref] Radiation Dose
CDDP (daily) [29] EBRT 8 mg/m2
Carboplatin (CI) [37] EBRT 12 mg/m2
Carboplatin (weekly) [39] EBRT 133 mg/m2
Topotecan daily on days 1–5 & 22–26 [70] EBRT 1 mg/m2
Topotecan daily on days 1–5 [71] Brachy 0.5 mg/m2
Topotecan plus CDDP EBRT no results yet
Irinotecan plus CDDP EBRT no results yet
Vinorelbine (weekly) [78]* Vinorelbine + paclitaxel EBRT 25 mg/m2 to toxic
Paclitaxel (weekly) + CDDP (every 21 days) [85] EBRT 50 mg/m2 and 50 mg/m2
Paclitaxel (weekly) + CDDP (weekly) [86] EBRT 50 mg/m2 and 30 mg/m2
Paclitaxel (weekly) +Carboplatin (weekly) [87] EBRT 50 mg/m2 and 2.5 AUC
Gemcitabine (weekly) [94] EBRT DLT not reached at 150 mg/m2
CDDP (weekly) +Gemcitabine (weekly) [100] EBRT 40 mg/m2 and 125 mg/m2
Gemcitabine first (weekly) +CDDP (weekly) [103] EBRT 50 mg/m2 and 40 mg/m2 to toxic
Capecitabine (twice daily) [109] EBRT 825 mg/m2
Capecitabine +CDDP (twice daily) [113] EBRT 825 mg/m2
  1. *To toxic when used with paclitaxel at 20mg/m2.